This HTML5 document contains 50 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00023001%3A_____%2F11%3A00002449%21RIV12-MZ0-00023001/
n15http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n16http://linked.opendata.cz/resource/domain/vavai/subjekt/
n14http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n12http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00023001%3A_____%2F11%3A00002449%21RIV12-MZ0-00023001
rdf:type
n14:Vysledek skos:Concept
rdfs:seeAlso
http://docstore.ingenta.com/cgi-bin/ds_deliver/1/u/d/ISIS/67971504.1/ben/cvp/2011/00000009/00000003/art00001/2B441E673361E6131332845653A524BB09FD3CDCA3.pdf?link=http://www.ingentaconnect.com/error/delivery&format=pdf
dcterms:description
An Expert Panel group of scientists and clinicians met to consider several aspects related to non-fasting and postprandial triglycerides (TGs) and their role as risk factors for cardiovascular disease (CVD). In this context, we review recent epidemiological studies relevant to elevated non-fasting TGs as a risk factor for CVD and provide a suggested classification of non-fasting TG concentration. Secondly, we sought to describe methodologies to evaluate postprandial TG using a fat tolerance test (FTT) in the clinic. Thirdly, we discuss the role of non-fasting lipids in the treatment of postprandial hyperlipemia. Finally, we provide a series of clinical recommendations relating to non-fasting TGs based on the consensus of the Expert Panel: 1). Elevated non-fasting TGs are a risk factor for CVD. 2). The desirable non-fasting TG concentration is <2 mmol/l (<180 mg/dl). 3). For standardized postprandial testing, a single FTT meal should be given after an 8 h fast and should consist of 75 g of fat, 25 g of carbohydrates and 10 g of protein. 4). A single TG measurement 4 h after a FTT meal provides a good evaluation of the postprandial TG response. 5). Preferably, subjects with non-fasting TG levels of 1-2 mmol/l (89-180 mg/dl) should be tested with a FTT. 6). TG concentration <= 2.5 mmol/l (220 mg/dl) at any time after a FTT meal should be considered as a desirable postprandial TG response. 7). A higher and undesirable postprandial TG response could be treated by aggressive lifestyle modification (including nutritional supplementation) and/or TG lowering drugs like statins, fibrates and nicotinic acid. An Expert Panel group of scientists and clinicians met to consider several aspects related to non-fasting and postprandial triglycerides (TGs) and their role as risk factors for cardiovascular disease (CVD). In this context, we review recent epidemiological studies relevant to elevated non-fasting TGs as a risk factor for CVD and provide a suggested classification of non-fasting TG concentration. Secondly, we sought to describe methodologies to evaluate postprandial TG using a fat tolerance test (FTT) in the clinic. Thirdly, we discuss the role of non-fasting lipids in the treatment of postprandial hyperlipemia. Finally, we provide a series of clinical recommendations relating to non-fasting TGs based on the consensus of the Expert Panel: 1). Elevated non-fasting TGs are a risk factor for CVD. 2). The desirable non-fasting TG concentration is <2 mmol/l (<180 mg/dl). 3). For standardized postprandial testing, a single FTT meal should be given after an 8 h fast and should consist of 75 g of fat, 25 g of carbohydrates and 10 g of protein. 4). A single TG measurement 4 h after a FTT meal provides a good evaluation of the postprandial TG response. 5). Preferably, subjects with non-fasting TG levels of 1-2 mmol/l (89-180 mg/dl) should be tested with a FTT. 6). TG concentration <= 2.5 mmol/l (220 mg/dl) at any time after a FTT meal should be considered as a desirable postprandial TG response. 7). A higher and undesirable postprandial TG response could be treated by aggressive lifestyle modification (including nutritional supplementation) and/or TG lowering drugs like statins, fibrates and nicotinic acid.
dcterms:title
Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement
skos:prefLabel
Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement
skos:notation
RIV/00023001:_____/11:00002449!RIV12-MZ0-00023001
n14:predkladatel
n16:ico%3A00023001
n4:aktivita
n7:N
n4:aktivity
N
n4:cisloPeriodika
3
n4:dodaniDat
n12:2012
n4:domaciTvurceVysledku
n15:7753403
n4:druhVysledku
n9:J
n4:duvernostUdaju
n10:S
n4:entitaPredkladatele
n11:predkladatel
n4:idSjednocenehoVysledku
187234
n4:idVysledku
RIV/00023001:_____/11:00002449
n4:jazykVysledku
n18:eng
n4:klicovaSlova
Postprandial triglycerides; non-fasting triglycerides; chylomicron remnants; very low density lipoprotein remnants; fat tolerance test; cardiovascular disease
n4:klicoveSlovo
n5:cardiovascular%20disease n5:very%20low%20density%20lipoprotein%20remnants n5:Postprandial%20triglycerides n5:fat%20tolerance%20test n5:non-fasting%20triglycerides n5:chylomicron%20remnants
n4:kodStatuVydavatele
AE - Stát Spojené arabské emiráty
n4:kontrolniKodProRIV
[BDE5EB4DD279]
n4:nazevZdroje
Current vascular pharmacology
n4:obor
n17:FB
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
10
n4:rokUplatneniVysledku
n12:2011
n4:svazekPeriodika
9
n4:tvurceVysledku
Bilianou, Helen Kovář, Jan Nordestgaard, Borge G Panotopoulos, George Kolovou, Genovefa D Lairon, Dennis Anagnostopoulou, Katherine Mikhailidis, Dimitri P Perez-Martinez, Pablo Ooi, Teik Chye
n4:wos
000290656600001
s:issn
1570-1611
s:numberOfPages
13